Home
News/PR
Global Monoclonal Antibody Therapeutics Market

Customizations Possible - Country-wise reports, Additional company profiles, Country/Regional reports and Other Customizations. Special Discounts Available. Global Monoclonal Antibody Therapeutics Market Size & Trends Report Segmented by Source (Human, Humanized, Chimeric), Application (Oncology, Autoimmune Diseases, Infectious, Hematologic, Ophthalmology) End User & Regional Forecast to 2030

Global Monoclonal Antibody Therapeutics Market Size & Trends Report Segmented by Source (Human, Humanized, Chimeric), Application (Oncology, Autoimmune Diseases, Infectious, Hematologic, Ophthalmology) End User & Regional Forecast to 2030

The global monoclonal antibody therapeutics market is set to witness a growth rate of ~12% in the next 5 years. Rising prevalence of chronic and autoimmune diseases, advancements in the technologies related to drug engineering and development, increased funding and investments into research and development, approval of monoclonal antibody therapies, increased acceptance of personalized medicine, and expanding applications of mAB therapy in various medical fields, are some of the key factors driving the monoclonal antibody therapeutics market. To learn more about the research report, download a sample report.

monoclonal-antibody-therapeutics-market

transparent

600

#12bece

‌
DESCRIPTION
TABLE OF CONTENT
METHODOLODY
SAMPLE DELIVERABLES

Report Overview

Monoclonal antibodies (mAbs) are antibodies produced by a clonal population of B cells and bind to a single target antigen. A therapeutic mAb is a homogenous collection of antibodies used to treat illnesses. mAbs are selected based on their affinity for a target antigen. The target can be a plasma protein, infectious organism, cell surface antigen, or IgG receptor, depending on the mechanism of treatment. mAbs are used in immunotherapies in different ways, like to stimulate the patient’s immune system, to modulate/inhibit a biochemical disease pathway to deliver a therapeutic radionuclide or drug to a target cell type. Therapeutic mAbs exhibit much higher specificity than small molecule drugs, which minimizes adverse side effects, especially when highly toxic drug substances must be delivered.

Monoclonal Antibody Therapeutics Market

To learn more about this report, download the PDF brochure

Increasing prevalence of chronic and autoimmune diseases to drive market growth

Severity and prevalence of chronic and autoimmune diseases are the key factors driving the market for mAB therapeutics. In 2023, 76.4% of adults over the age of 18 in the US were suffering from at least one chronic illness, this marks an increase from 72.3% reported in 2013. In addition, participants with multiple chronic conditions (two or more) also showed an increase from 47.3% to 51.4% during the same time period (Source: CDC). Furthermore, autoimmune diseases affect 5 to 10% of the population in industrialized countries (Source: Global Autoimmune Institute). The growing prevalence of such chronic and autoimmune diseases is driving the global need for mAbs or monoclonal antibodies which are precise and strongly effective directed therapies. The high specificity of mAbs helps in protecting healthy tissues from damage which greatly improves outcomes. mAbs are most suitable for the treatment of complex immune related disorders due to their ability to target disease related epitope markers, leading to increased mAbs market growth.

Advancements in the technologies related to drug engineering and development to propel market growth

Advancements in the drug engineering and therapy development technologies are propelling the growth of the monoclonal antibody therapeutics market. Modern advances, including recombinant DNA, high-throughput screening, and complex cell line development, have pushed therapies to the limits of efficacy, safety, and specificity of treatment with monoclonal antibodies. These approaches enable production of both humanized and completely human, as shielded, or bispecific antibodies as well as those with improved therapeutic indexes and less side effects. In addition, the efficacy of mAb of cancer and other diseases can be increased by antibody-drug conjugates (ADCs) combining mAbs specificity and potently active drugs. These improvements shorten the timescale taken to develop drugs and reduce production expenses, expanding the scope of treatable conditions and rendering the market bigger.

Monoclonal Antibody Therapeutics Market - Segmentation

To learn more about this report, download the PDF brochure

Competitive Landscape Analysis

The global monoclonal antibody therapeutics market is marked by the presence of established and emerging market players such as F. Hoffmann-La Roche Ltd; AbbVie Inc.; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb (BMS); Amgen Inc.; Novartis AG; Eli Lilly and Company; Sanofi; and AstraZeneca; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Report Scope

Report Metric	Details
Base Year Considered	2024
Historical Data	2023 - 2024
Forecast Period	2025 - 2030
Growth Rate	~12%
Market Drivers	Rising prevalence of chronic and autoimmune diseases Advancements in the technologies related to drug engineering and development Increased funding and investments into research and development Approval of monoclonal antibody therapies Increased acceptance of personalized medicine Expanding applications of mAB therapy in various medical fields medicine
Attractive Opportunities	Rising demand in emerging markets Next-generation antibody platforms Expansion into rare and orphan diseases Combination therapies and ADCs
Segment Scope	Source, Application, End User
Regional Scope	North America (US & Canada) Europe (UK, Germany, France, Italy, Spain, Rest of Europe) Asia Pacific (China, India, Japan, Rest of Asia Pacific) Latin America Middle East & Africa
Key Companies Mapped	F. Hoffmann-La Roche Ltd; AbbVie Inc.; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb (BMS); Amgen Inc.; Novartis AG; Eli Lilly and Company; Sanofi; and AstraZeneca; among others
Report Highlights	Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis

Global Monoclonal Antibody Therapeutics Market Segmentation

This report by Medi-Tech Insights provides the size of the global monoclonal antibody therapeutics market at the regional- and country-level from 2023 to 2030. The report further segments the market based on source, application, end user.

Market Size & Forecast (2023-2030), By Source, USD Million

Human Source
Humanized Source
Chimeric Source
Others

Market Size & Forecast (2023-2030), By Application, USD Million

Oncology
Autoimmune Diseases
Infectious Diseases
Hematologic Diseases
Ophthalmology
Others

Market Size & Forecast (2023-2030), By End User, USD Million

Hospitals
Long-term Care Facilities
Others

Market Size & Forecast (2023-2030), By Region, USD Million

North America
- US
- Canada
Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
Latin America
Middle East & Africa

Key Strategic Questions Addressed

What is the market size & forecast of the monoclonal antibody therapeutics market?
What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the monoclonal antibody therapeutics market?
What are the key trends defining the market?
What are the major factors impacting the market?
What are the opportunities prevailing in the market?
Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
Who are the major players operating in the market?
What are the key strategies adopted by players?

Introduction
- Introduction
- Market Scope
  - Market Definition
  - Segments Covered
  - Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2025-2026)
Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
  - Bottom-Up Approach
  - Top-Down Approach
- Market Forecasting
Executive Summary
- Monoclonal Antibody Therapeutics Market Snapshot (2025-2030)
- Segment Overview
- Regional Snapshot
- Competitive Insights

Market Overview
- Market Dynamics
  - Drivers
    - Rising prevalence of chronic and autoimmune diseases
    - Advancements in the technologies related to drug engineering and development
    - Increased funding and investments into research and development
    - Approval of monoclonal antibody therapies
    - Increased acceptance of personalized medicine
    - Expanding applications of mAB therapy in various medical fields medicine
  - Restraints
    - High production and development costs
    - Stringent regulatory requirements
    - Patent expirations and biosimilar competition
    - Complexities in formulation and stability
  - Opportunities
    - Rising demand in emerging markets
    - Next-generation antibody platforms
    - Expansion into rare and orphan diseases
    - Combination therapies and ADCs
  - Key Market Trends
    - Adoption of artificial intelligence (AI) in drug discovery
    - Rise of bispecific antibodies
    - Biosimilar development and approvals
  - Unmet Market Needs
  - Industry Speaks

Global Monoclonal Antibody Therapeutics Market Size & Forecast (2023-2030), By Source, USD Million
- Introduction
- Human Source
- Humanized Source
- Chimeric Source
- Others
Global Monoclonal Antibody Therapeutics Market Size & Forecast (2023-2030), By Application, USD Million
- Introduction
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Hematologic Diseases
- Ophthalmology
- Others
Global Monoclonal Antibody Therapeutics Market Size & Forecast (2023-2030), By End User, USD Million
- Introduction
- Hospitals
- Long-term Care Facilities
- Others
Global Monoclonal Antibody Therapeutics Market Size & Forecast (2023-2030), By Region, USD Million
- Introduction
- North America Monoclonal Antibody Therapeutics Market Size & Forecast (2023-2030), By Country, USD Million
  - US
    - Market Size & Forecast, By Source (USD Million)
    - Market Size & Forecast, By Application (USD Million)
    - Market Size & Forecast, By End User (USD Million)
  - Canada
    - Market Size & Forecast, By Source (USD Million)
    - Market Size & Forecast, By Application (USD Million)
    - Market Size & Forecast, By End User (USD Million)
- Europe Monoclonal Antibody Therapeutics Market Size & Forecast (2023-2030), By Country, USD Million
  - UK
    - Market Size & Forecast, By Source (USD Million)
    - Market Size & Forecast, By Application (USD Million)
    - Market Size & Forecast, By End User (USD Million)
  - Germany
    - Market Size & Forecast, By Source (USD Million)
    - Market Size & Forecast, By Application (USD Million)
    - Market Size & Forecast, By End User (USD Million)
  - France
    - Market Size & Forecast, By Source (USD Million)
    - Market Size & Forecast, By Application (USD Million)
    - Market Size & Forecast, By End User (USD Million)
  - Italy
    - Market Size & Forecast, By Source (USD Million)
    - Market Size & Forecast, By Application (USD Million)
    - Market Size & Forecast, By End User (USD Million)
  - Spain
    - Market Size & Forecast, By Source (USD Million)
    - Market Size & Forecast, By Application (USD Million)
    - Market Size & Forecast, By End User (USD Million)
  - Rest of Europe
    - Market Size & Forecast, By Source (USD Million)
    - Market Size & Forecast, By Application (USD Million)
    - Market Size & Forecast, By End User (USD Million)
- Asia Pacific (APAC) Monoclonal Antibody Therapeutics Market Size & Forecast (2023-2030), By Country, USD Million
  - China
    - Market Size & Forecast, By Source (USD Million)
    - Market Size & Forecast, By Application (USD Million)
    - Market Size & Forecast, By End User (USD Million)
  - Japan
    - Market Size & Forecast, By Source (USD Million)
    - Market Size & Forecast, By Application (USD Million)
    - Market Size & Forecast, By End User (USD Million)
  - India
    - Market Size & Forecast, By Source (USD Million)
    - Market Size & Forecast, By Application (USD Million)
    - Market Size & Forecast, By End User (USD Million)
  - Rest of Asia Pacific
    - Market Size & Forecast, By Source (USD Million)
    - Market Size & Forecast, By Application (USD Million)
    - Market Size & Forecast, By End User (USD Million)
- Latin America (LATAM) Monoclonal Antibody Therapeutics Market Size & Forecast (2023-2030), USD Million
  - Market Size & Forecast, By Source (USD Million)
  - Market Size & Forecast, By Application (USD Million)
  - Market Size & Forecast, By End User (USD Million)
- Middle East & Africa (MEA) Monoclonal Antibody Therapeutics Market Size & Forecast (2023-2030), USD Million
  - Market Size & Forecast, By Source (USD Million)
  - Market Size & Forecast, By Application (USD Million)
  - Market Size & Forecast, By End User (USD Million)

Competitive Landscape
- Key Players and their Competitive Positioning
  - Key Player Comparison
  - Segment-wise Player Mapping
  - Market Share Analysis (2024)
  - Company Categorization Matrix
    - Dominants/Leaders
    - New Entrants
    - Emerging Players
    - Innovative Players
  - Key Strategies Assessment, By Player (2022-2025)
    - New Product Launches
    - Partnerships, Agreements, & Collaborations
    - Mergers & Acquisitions
    - Geographic Expansion

Company Profiles*

(Business Overview, Financial Performance**, Products Offered, Recent Developments)

Hoffmann-La Roche Ltd
AbbVie Inc.
Johnson & Johnson Services, Inc.
Merck & Co., Inc
Bristol-Myers Squibb (BMS)
Amgen Inc.
Novartis AG
Eli Lilly and Company
Sanofi
AstraZeneca
Other Prominent Players

Note: *Indicative list

**For listed companies

The study has been compiled based on extensive primary and secondary research.

Secondary Research (Indicative List)

Monoclonal Antibody Therapeutics Market - Secondary Research

Primary Research

To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.

Supply Side Stakeholders:

Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants

Demand Side Stakeholders:

Stakeholders from Hospitals; Long-term Care Facilities, and Others

Breakdown of Primary Interviews

Monoclonal Antibody Therapeutics Market - Primary Interviews

Market Size Estimation

Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts

Data Triangulation

Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data

Monoclonal Antibody Therapeutics Market - Sample Deliverables

Monoclonal Antibody Therapeutics Market - Key Players

Get a sample report for competitive landscape analysis

Features of the Report

Comprehensive Market Coverage
Market Size and Forecast
Geographic & Segment Deep Dives
Strategic Insights & Competitive Landscape
Timely & Updated Data
Growth Indicators & Future Outlook
Quick Turnaround on Queries
Analyst Support
Report Customization Available
Reports in PDF & Excel

Order Report